Ghasemi Tahrir, Farzaneh
Gupta, Manish
Myers, Valerie
Gordon, Jennifer
Cheung, Joseph Y.
Feldman, Arthur M.
Khalili, Kamel
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (P30MH092177, P30MH092177)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL123093, R01HL123093)
Article History
Received: 14 June 2018
Accepted: 10 December 2018
First Online: 21 May 2019
Competing Interests
: A.M.F. and K.K. have a pending US patent #611934,483 for BAG3 as a target for heart failure therapy. A.M.F. and J.Y.C. have a pending US patent #621205,990 for BAG3 composition and methods. Exclusive rights to the patents have been optioned by Temple University to Renovacor, Inc. A.M.F. and J.Y.C. hold equity in Renovacor, Inc.